Early Development of Arterial Hypertension in an Infant with Valsartan Fetopathy

Christina Schindera1, Benedikt M Huber2, Mathias Nelle1, Boris Utsch1, Sybille Tschumi2 and Roland Gerull1

1University Hospital Inselspital Berne Childrens Hospital, Neonatology, Berne, Switzerland
2Triemli City Hospital Zurich, Pediatrics, Switzerland
3University Hospital Inselspital Berne, Childrens Hospital, Pediatric Nephrology, Berne, Switzerland

Abstract

The renin-angiotensin-aldosterone-system (RAAS) plays a pivotal role for normal kidney development. We present the case of a 34-year old second gravida who was treated with valsartan during the entire pregnancy and presented at 35 weeks of gestation with preterm labour and complete anhydramnios. After spontaneous delivery the eutropic male infant showed typical signs of sartan fetotoxicity including neonatal anuria, enlarged hyperechogenic kidneys, initial arterial hypotension, limb contractures, skull bone hypoplasia and a narrow chest. During the first days of life arterial hypertension developed and persisted until last follow-up at 24 months. Antihypertensive therapy with amlodipine was necessary from 7 months of life until last follow-up. Valsartan exposure especially during the second half of pregnancy causes valsartan fetotoxicity, which can lead to progressive arterial hypertension requiring antihypertensive medication. Close monitoring of patients with valsartan fetopathy is essential.

Keywords: Renal toxicity; Renal damage; Hypertension; Drug reaction; Neonatal complications

Introduction

The renin-angiotensin-aldosterone system (RAAS) is not only involved in the regulation of renal function and blood pressure but plays a pivotal role in normal kidney development [1]. Pharmacological interruption of fetal RAAS-signaling with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor type 1 (AT1) antagonists impairs metanephrogenesis, as well as tubular and nephrovascular development [1,2]. The wide spectrum of clinical manifestations ranges from reversible effects on amniotic fluid after drug withdrawal as well as late preterm and term gestations with only minor problems during the neonatal period to death as a result of severe complications of renal failure [3,4]. While long-term sequelae have been shown after ACE inhibitor fetopathy [5], reports of AT1 antagonist (sartan) fetotoxicity focus on the perinatal and neonatal outcome.

We present the case of a prematurely born male infant with typical signs of valsartan fetopathy and recovery of renal function during the first week of life. However, progressive arterial hypertension developed during infancy necessitating antihypertensive therapy. To our knowledge, this is the first case report on valsartan fetopathy causing prolonged arterial hypertension and requirement of antihypertensive medication in early childhood.

Case Report

5 month prior to pregnancy an otherwise healthy 34-year old woman with essential hypertension (blood pressure 160/90 mmHg) was treated with valsartan 80 mg daily. Valsartan was continued for the full length of her second pregnancy because the primary care physician was unaware of potential teratogenicity. Blood pressure was reduced to 130/85 mmHg. Regular sonographic examinations were normal including an ultrasound performed at 33 weeks of gestational age. At 35 weeks of gestation the woman presented with premature labour and complete anhydramnios without premature rupture of membranes. She delivered an eutrophic male infant weighing 3005 g (percentile 80) and measuring 52.0 cm (percentile 96), with a head circumference of 32.6 cm (percentile 30) and umbilical artery pH 7.23. Apgar score was 6 at one minute (1 for muscle tone, respiration, cyanosis and reflexes, respectively) and 9 at five and ten minutes (1 for peripheral cyanosis).

Typical signs of sartan fetotoxicity were present including neonatal anuria, arterial hypotension, limb contractures, hypocalvaria and a narrow chest. There were no signs of respiratory distress and lung hypoplasia could be excluded by chest x-ray.

Because of complete anuria during the first day of life furosemide (0.34 mg/kg body weight) was administered at 22 hours of life followed by a single micturition (4ml of urine). However, anuria persisted and the boy became increasingly oedematous. After a second dose of furosemide (2.7 mg/kg body weight) at 38 hours of life in combination with a dopamine infusion (4 μg/kg/min) over 24 hours, diuresis finally initiated at 48 hours of life and was then within the normal range (> 1 ml/kg body weight/hour) (Figure 1).

Arterial hypotension occurring in the first hour of life (mean blood pressure 25-35mmHg) showed no sustained response to crystalloids and hydrocortisone. The blood pressure normalized under dopamine administration. A borderline hypertension with mean arterial pressures between 52-62 mmHg developed from day 8 on and persisted until discharge at day 18. Echocardiography was normal.

*Corresponding author: Roland Gerull MD, University Hospital Inselspital Berne, Pediatric Intensive Care / Neonatology, Effingerstr. 102, CH-3010 Bern, Switzerland, Tel: 0041-31- 632 0855; Fax: 0041-31-632 1405; E-mail: roland.gerull@insel.ch

Received December 19, 2011; Accepted February 22, 2012; Published February 26, 2012

Citation: Schindera C, Huber BM, Nelle M, Utsch B, Tschumi S, et al. (2012) Early Development of Arterial Hypertension in an Infant with Valsartan Fetopathy. J Neonatal Biol 1:103. doi:10.4172/2167-0897.1000103

Copyright: © 2012 Schindera C, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Maximum serum creatinine was 245 μmol/l (2.8 mg/dl) on day 3 and decreased to normal age-related values within 14 days (Figure 1). There was no electrolyte or acid-base imbalance. Urine analysis showed glucosuria and urine protein imbalance on the 10th day of life [6], requiring the start of anti-hypertensive therapy with amlodipine at 7 months of age. In parallel renal sonography reported hyperechogenic renal parenchyma and diminished corticomedullary differentiation until 16 months of life. These complications are known from children with fetal exposure to ACE inhibitors; in those children arterial hypertension first occurred between three and ten years of age [5]. The course of arterial hypertension and morphological changes remain unclear making close follow-up necessary.

In summary, valsartan exposure during second half of pregnancy causes fetotoxicity with neonatal acute anuric renal failure. After initial recovery of renal functioning, progressive arterial hypertension may develop necessitating antihypertensive medication. Therefore, close follow-up of children with valsartan fetopathy is essential.

Discussion

Renal development depends on normal RAAS-function and disorders either due to mutations in RAAS-genes or due to pharmacological inhibition of RAAS-components result in renal tubular dysgenesis. This severe developmental disorder is associated with significant fetal and neonatal morbidity and mortality [2-4] as well as long-term sequelae for renal function and blood pressure [5]. Fetal AT1 and angiotensin II receptor type 2 (AT2) receptors are localized to renal differentiating structures in a temporally and spatially specific pattern. AT2 receptors are more predominant in the undifferentiated renal tissue during the first half of pregnancy, while AT1 receptors are expressed in more differentiated tissue in the second half of pregnancy, responsible for final differentiation of nephrovascular architecture. Selective blockade of AT1 receptors during second half of pregnancy is therefore associated with severe tubular dysgenesis and renal impairment. Accordingly, our patient probably developed renal hypertension due to arterial hypertension in-utero and consecutive anhydramnios in late pregnancy. In contrast, fetal complications are less frequently observed with maternal AT1 receptor antagonist treatment during first half of pregnancy [4,7,8], where AT1 receptors seem to play a minor role [9]. When AT1 receptor antagonist treatment is withdrawn during early pregnancy, the fetotoxic effect of anhydramnios may be reversible [7].

In the so far largest case series, Alwan et al. [3,4] reviewed 20 cases of fetal second and third trimester exposure to AT1 receptor antagonists. Twenty-five percent of the pregnancies were prematurely interrupted because of stillbirth or termination, 27% of the remaining 15 live births died within 4 days. Regarding fetal and neonatal renal function, 90% had oligohydramnios, 53% of live births developed anuria after birth and 55% of the fetuses showed enlarged kidneys. However no long-term follow-up on the surviving neonates was conducted in this study; therefore further development of renal function remains unclear.

In the presented case, an initially favourable course of renal function was observed, with normal diuresis following repetitive pharmacological stimulation within the first days of life and serum creatinine normalized within two weeks of life and remained within normal range until the last follow-up at 24 months of life. However, renal structural alterations persisted and arterial hypertension developed during infancy necessitating the start of an antihypertensive treatment at seven months of age. In parallel renal sonography reported hyperechogenic renal parenchyma and diminished corticomedullary differentiation until 16 months of life. These complications are known from children with fetal exposure to ACE inhibitors; in those children arterial hypertension first occurred between three and ten years of age [5]. The course of arterial hypertension and morphological changes remain unclear making close follow-up necessary.

References

1. Chen Y, Lasaitiene D, Friberg P (2004) The renin-angiotensin system in kidney development. Acta Physiol Scand 181: 529-535.
2. Quan A (2006) Fetopathy associated with exposure to angiotensin converting enzyme inhibitors and angiotensin receptor antagonists. Early Hum Dev 82: 23-28.
3. Alwan S, Polifka JE, Friedman JM (2005) Angiotensin II receptor antagonist treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 73: 123-130.
4. Alwan S, Polifka JE, Friedman JM (2005) Addendum: sartan treatment during pregnancy. Birth Defects Res A Clin Mol Teratol 73: 904-905.
5. Laube GF, Kemper MJ, Schubiger G, Neuhaus TJ (2007) Angiotensin-converting enzyme inhibitor fetopathy: long-term outcome. Arch Dis Child Fetal Neonatal Ed 92: F402-403.
6. (1996) Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group on Hypertension Control in Children and Adolescents. Pediatrics 98: 649-658.
7. Berkane N, Carlier P, Verstraete L, Mathieu E, Heim N, et al. (2004) Fetal toxicity of valsartan and possible reversible adverse side effects. Birth Defects Res A Clin Mol Teratol 70: 547-549.
8. Serreau R, Luton D, Macher MA, Delezoide AL, Garel C, et al. (2005) Developmental toxicity of the angiotensin II type 1 receptor antagonists during human pregnancy: a report of 10 cases. BJOG 112: 710-712.
9. Norwood VF, Craig MR, Harris JM, Gomez RA (1997) Differential expression of angiotensin II receptors during early renal morphogenesis. Am J Physiol 272: R662-668.